

# Rheumatoid Arthritis Therapeutic and Overview Pipeline Review H2

*Global Rheumatoid Arthritis Drugs and Companies Pipeline Review H2 2016*

PUNE, INDIA, November 15, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Rheumatoid Arthritis](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/575881-rheumatoid-arthritis-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and

universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
- The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

#### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

#### Table of Contents

Table of Contents 2

Introduction 12

Rheumatoid Arthritis Overview 13

Therapeutics Development 14

Rheumatoid Arthritis - Therapeutics under Development by Companies 16

Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 34

Rheumatoid Arthritis - Pipeline Products Glance 37

Rheumatoid Arthritis - Products under Development by Companies 41

Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 69

Rheumatoid Arthritis - Companies Involved in Therapeutics Development 72

Rheumatoid Arthritis - Therapeutics Assessment 294  
Drug Profiles 328  
Rheumatoid Arthritis - Dormant Projects 1016  
Rheumatoid Arthritis - Discontinued Products 1064  
Rheumatoid Arthritis - Product Development Milestones 1075

Access Report @ <https://www.wiseguyreports.com/reports/575881-rheumatoid-arthritis-pipeline-review-h1-2016>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/353979641>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.